Screener
D&A at other companies
Other financials
Where this comes from
Reported directly by Astrana Health in its filing.
Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.
The source filing: Astrana Health’s 10-Q, filed May 8, 2026.
- Filed
- May 8, 2026, 6:01 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-213157
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Cash flows from operating activities | ||
| Net income | $13,131 | $6,221 |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||
| Depreciation and amortization | 15,479 | 6,849 |
| Amortization of debt issuance cost | 1,134 | 691 |
| Share-based compensation | 9,895 | 7,811 |
| Non-cash lease expense | 2,005 | 1,287 |
| Deferred tax | 1,907 | (358) |
ITEM 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
FAQ
- What is Astrana Health's D&A?
- Astrana Health (ASTH) reported D&A of $15.48M in Q1 2026.
- How has Astrana Health's D&A changed year-over-year?
- Astrana Health's D&A increased by 126.0% year-over-year, from $6.85M to $15.48M.
- What is the long-term trend for Astrana Health's D&A?
- Over 4 years (2021 to 2025), Astrana Health's D&A has grown at a 27.1% compound annual growth rate (CAGR), from $17.52M to $45.75M.
- What does D&A mean?
- Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.
Ask your AI about Astrana Health's d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude